Sublingual formulation with water-soluble cocrystals of acetylsalicylic acid with citric acid, sodium bicarbonate, and l-theanine for the treatment of acute myocardial infarction

A method of manufacturing a composition comprising aspirin, citric acid, sodium bicarbonate, and L-theanine.

A cocrystal aspirin, citric acid, sodium bicarbonate, L-theanine sublingual formulation, wherein the formulation can bypass the hepatic first pass effect, with enhanced dissolution rate and bioavailability when a rapid onset of action is desired, compared to the oral route of conventional aspirin.

A cocrystal aspirin, citric acid, sodium bicarbonate, L-theanine sublingual formulation with an expected significantly reduced median platelet aggregation inhibition time compared to the oral route of conventional aspirin.

A water-soluble cocrystal product of acetylsalicylic acid with citric acid, sodium bicarbonate, and L-theanine administered sublingually for the treatment of acute myocardial infarction.

Cocrystal compositions of a drug from a specified drug class, and the enantiomers, L- and D-isomers, D, L-racemic mixture, S- and R-isomers, S, R-racemic mixtures, all rotamers, tautomers, salt forms, and hydrates of the alpha and beta amino acids of theanine in which the N-substituted functional R1-group [C4 or gamma-CH2—C(O)—NR1] may contain linear, cyclic, or branched alkyl groups and derivatives thereof;

• linear, cyclic or branched alkenyl groups and derivatives thereof;
• and aromatic radicals (which may be aryl radicals) and derivatives thereof making up all the analogue forms of theanine.

A dosage form comprising a composition comprising aspirin, citric acid, sodium bicarbonate, and L-theanine.

A method of treating acute myocardial infarction in a subject in need thereof, comprising administering to the subject a cocrystal aspirin, citric acid, sodium bicarbonate, and L-theanine sublingual formulation.